clinical trial · NCT07566429
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease
Bayer·phase2·not yet recruiting·n = 8
Parkinson DiseaseAB-1005
brief summary
The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate Parkinson's Disease (PD).
started
Jul 27, 2026
primary completion
Dec 15, 2028
completion
Jun 15, 2032
last updated
May 5, 2026
official title
A Phase 2, Open-label, Single Group, Fixed-dose Study to Evaluate the Safety and Efficacy of a Single Bilateral Intraputaminal Administration of AB-1005 (AAV2-GDNF Gene Therapy) in Japanese Participants With Moderate Stage Parkinson's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol